Health News

PRP may be superior to hyaluronic acid for improvement of pain, function in patients with OA

This is encouraging!!!! Aas HA injections are routinely being denied by Premera, Regence, Aetna and soon to be many others, the use of our own natural platelets has shown promise. Contact me for more info!

  • LOS ANGELES — Use of intra-articular platelet-rich plasma significantly improved pain and function in patients with osteoarthritis at 6 months and may be a superior alternative to hyaluronic acid, according to study findings presented at the Arthroscopy Association of North America Annual Meeting.

“Our study suggests that lower-leukocyte [platelet-rich plasma] is … effective in the treatment of knee osteoarthritis, with superior and meaningful clinical differences in favor of [platelet-rich plasma] over [hyaluronic acid] at 6 months and 12 months,” Annemarie Tilton, BBA, said during her presentation.

Annemarie Tilton

 

 

Tilton and colleagues randomly assigned 99 patients with a minimum of 3 months of symptomatic unilateral knee osteoarthritis (OA) and Kellgren Lawrence grade 1-3 OA to receive 3 weekly injections of either platelet-rich plasma (PRP) or hyaluronic acid (HA). Patients completed Lysholm, IKDC, WOMAC and VAS pain surveys and underwent clinical examination at 6 weeks, 12 weeks and 24 weeks after index treatment. During each treatment visit and at 3-month and 6-month follow-up, patients also underwent ultrasound-guided knee aspiration for synovial fluid analysis.

According to Tilton, patients who had a low BMI, as well as patients with Kellgren Lawrence grade 1 OA, tended to be responders to treatment. Additionally, PRP fold was not found to be a factor in response to treatment.

“Results also showed that the PRP groups had clinically significantly greater scores in IKDC at 6 months and at 1 year, with a minimally clinically important difference of greater than 10,” Tilton said.

 

Patients in the PRP group also had lower pain scores at 6 months and 1 year vs. the HA group, according to study results. At 3 months post-treatment, biologic outcomes showed the PRP group trended toward lower values of interleukin-1 beta and tumor necrosis factor-alpha. – by Casey Tingle

Reference:

Cole B, et al. Paper #SS-57. Presented at: Arthroscopy Association of North America Annual Meeting. April 23-25, 2015; Los Angeles.

Disclosure: Tilton reports no relevant financial disclosures.

 

Comments are closed.

BELLEVUE OFFICE

1601 116th AVE NE
Suite 111
Bellevue WA 98004
425-899-4810

KIRKLAND OFFICE

12333 NE 130th Lane
Suite Tan 400
Kirkland, WA 98034
425-899-4810